Arbutus Biopharma Corporation (ABUS) vs Lexicon Pharmaceuticals, Inc. (LXRX)
Arbutus Biopharma Corporation and Lexicon Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ABUS vs LXRX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Arbutus Biopharma Corporation (ABUS) | Lexicon Pharmaceuticals, Inc. (LXRX) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $14.08M | $49.80M |
| Net income (latest FY) | $-33.50M | $-50.34M |
| Revenue growth (5y CAGR) | 15.3% | 15.7% |
| Net margin | -237.9% | -101.1% |
| Return on equity | -43.7% | -46.8% |
| P/E ratio | 5.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Performance — ABUS vs LXRX
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Arbutus Biopharma Corporation (ABUS) | Lexicon Pharmaceuticals, Inc. (LXRX) | |
|---|---|---|
| 1-year return | 36.6% | 97.9% |
| 3-year return | 83.5% | -17.9% |
| 5-year return | 39.3% | -59.0% |
| 10-year return | 21.3% | -86.9% |
| 52-week range | $3.04–$5.10 | $0.64–$2.53 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ABUS vs LXRX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ABUS's full financials → Open LXRX's full financials →More comparisons
Frequently asked questions
Which is bigger, ABUS or LXRX?
Lexicon Pharmaceuticals, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, ABUS or LXRX?
Over the last five fiscal years, Lexicon Pharmaceuticals, Inc. grew revenue faster — 15.7%/yr versus 15.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.